HC Wainwright & Co. Maintains Buy on Ikena Oncology, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has maintained a Buy rating on Ikena Oncology (NASDAQ:IKNA) with an unchanged price target of $11.

March 12, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ikena Oncology maintains a Buy rating from HC Wainwright & Co. with a steady price target of $11, as per analyst Andres Maldonado.
The reaffirmation of a Buy rating and a price target of $11 by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on Ikena Oncology's stock price. The analyst's continued support suggests a belief in the company's value and prospects, which can be a positive signal to the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90